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Background. HER2/neu positive breast tumors are difficult to treat. About 25 to 30% of invasive breast 
tumors overexpress the HER2/neu oncogene. These tumors are aggressive and become resistant to 
chemotherapeutic drugs. 3,3′-diindolylmethane (DIM), the active metabolite of indole-3-carbinol, a 
naturally occurring compound found in cruciferous vegetables, has been found to have anti-cancer 
properties in both humans and animals. DIM has been shown to induce cell cycle arrest and apoptosis in 
animal breast cancer models. Because HER2/neu overexpression confers resistance to paclitaxel, and DIM 
has anti-tumor effects, we hypothesized that DIM will enhance the cytotoxic effects of paclitaxel, a 
common taxane drug, on human Her2/neu breast cancer cells by potentiating its effect on cell cycle and 
stimulating apoptosis.  
 
Methods. The MDA-MB-435eB1 human Her2/neu breast cancer cells were treated with varying 
concentrations of DIM and paclitaxel. The cells were analyzed at different time points (24, 48, and 72 h). 
Proliferation was measured by a commercial cell proliferation assay (Promega Procheck Assay). Cell-cycle 
analysis and apoptosis were determined by flow cytometry. Western blot analysis was performed on to 
determine the effect of DIM and/or paclitaxel on the proteins involved in apoptosis, and epidermal growth 
factor-induced activation of HER2/neu and ERK1/2 signaling proteins.   
 
Results. Both DIM and paclitaxel exhibited time and concentration dependent inhibition of cell 
proliferation.   TUNEL assay indicated that the combination also increased the number of apoptotic cells 
more than either agent alone. The presence of cleaved poly (ADPRibose) polymerase (PARP) significantly 
increased in the combination treatment, whereas Bcl-2 is decreased.  DIM alone decreased the activation of 
the Her2/neu receptor; the combination decreased the activation of ERK1/ERK2. 
 
Conclusions. DIM in combination with paclitaxel synergistically inhibits growth of Her2/neu human breast 
cancer cells through G2M phase cell-cycle arrest and induction of apoptosis/necrosis. The Her2/neu 
receptor and its downstream signaling protein ERK1/2 appear to be involved in DIM’s affect on cell 
growth and differentiation, whereas apoptosis appears to be mediated through the mitochondrial pathway 
(Bcl-2/ PARP). It appears DIM, a naturally occurring, nontoxic compound, may be a beneficial addition to 
a traditional (taxane-based) chemotherapy regimen.   
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INTRODUCTION 
 
Women with breast tumors that are positive for the HER2/neu gene are difficult to treat 
[1, 2]. About 25 to 30% of all invasive breast tumors overexpress Her2/neu/erbB2 [1]. 
This gene increases the aggressiveness of breast cancer and resistance to 
chemotherapeutic drugs, including paclitaxel (Taxol) and other taxanes [2–5]. 
Chemotherapeutic resistance leads to a high reoccurrence rate and ultimately affects 
long-term survival. Attempts to improve chemosensitization of the HER2/neu positive 
tumors to chemotherapeutic agents have met with limited success. Thus, there is a need to 
develop treatment strategies that will enhance the effectiveness of these drugs for this 
patient population. 
 
Most tested strategies for improving chemotherapeutic effect involve combining 
traditional chemotherapeutic agents in varying dose strengths, time courses, and drug 
combinations. However, very rarely have non-traditional agents been used with more 
traditional chemotherapies to study their effect.  Numerous studies have demonstrated the 
anti-cancer effects of food components such as quercetin, curcumin, and resveratrol 
[6]. 3,3′-diindolylmethane (DIM) is a naturally occurring active component of cruciferous 
vegetables that is formed from its precursor indole 3 carbinol (I3C). I3C and DIM have 
been shown to protect against many neoplasms, including prostate, cervical, and breast 
cancer [7–10]. In human breast cancer cells, I3C inhibits proliferation [11, 12], blocks 
cells in the G1 phase of the cell cycle [21], and induces apoptosis [13].  I3C and 
tamoxifen were found to act separately and/or cooperatively in inhibiting growth of 
estrogen receptor positive cells [14]. Recently, DIM was also shown to decrease 
proliferation of estrogen receptor-positive and estrogen receptor-negative breast cancer 
cells by inducing a G1 cell cycle arrest [15] and by stimulating apoptosis [16]. DIM 
induced apoptosis in breast cancer cells through the mitochrondrial pathway [17] by 
inhibiting Akt and nuclear factor-_B pathway [17–20]. 
 
Studies have shown that HER2/neu overexpression in breast cancer cells confers 
resistance to the mitotic effects of paclitaxel [21–24]. DIM induces cell death in breast 
cancer cells. However, it is not known whether DIM can overcome the chemoresistance 
of cancer cells.  Therefore, we investigated whether DIM will enhance the cytotoxic 
effects of paclitaxel by through alterations in ERK1/ERK2 signaling. In this study, we 
used MDA-MB-435 human breast cancer cells transfected with HER2/neu/erbB2 (MDA-
MB-435eB1) to determine the individual and combined effects of DIM and paclitaxel on 
cell growth, cell cycle, and apoptosis. We also investigated apoptotic pathways that may 
be involved in the interactions of DIM and paclitaxel. 
 
 
MATERIALS AND METHODS 
 
 
Cell Culture 
 
Dr. Dihua Yu at the University of Texas M.D. Anderson Cancer Center (Houston, TX) 
kindly provided 435eb1 Her2/neu positive, estrogen/progesterone receptor negative 
human breast carcinoma cells. Cells were grown in DMEM/F12 medium supplemented 
with 10% fetal bovine serum (FBS). Every 4 weeks the cells were passaged with media 
supplemented with G418 (800 ug/ml). 
 
 
 
Materials 
 
Bioresponse DIM was kindly provided by Dr. Michael Zeligs (BioResponse, LLC, 
Boulder, CO). Polyclonal antibody to BCL-2, bax, and PARP were obtained from Santa 
Cruz Biotechnology. Anti-ERK1/ERK2, and anti-phospho ERK1/ERK2 were obtained 
from Cell Signaling. 
 
Cell Survival Assay 
 
435eb1 cells were plated in 96-well plates and incubated in DMEM/F12 with 5% FBS for 
24 h. Cells were then treated with 0, 5, 10, and 15 uM DIM for 0, 24, 48, and 72 h. The 
number of viable cells was determined with ProCheck cell viability assay. 
 
Cell Cycle/Flow Cytometric Analysis 
 
435eb1 cells were plated in T-175 flasks and incubated in DMEM/F12 with 5% FBS for 
24 h. Cells were then treated with vehicle, 15 uM DIM, 10 nM Paclitaxel, and 15 uM 
DIM +10 nM Paclitaxel and incubated for an additional 72 h. Attached and floating cells 
were harvested, fixed in 70% ethanol, digested with RNase A, stained with propidium 
iodide, and analyzed by fluorescence-activated cell sorting using a Beckman Coulter XL-
MCLTM flow cytometer with System II Software. 
 
Apoptosis Assay 
 
435eb1 cells were plated in T-175 flasks and incubated in DMEM/F12 with 5% FBS for 
24 h. Cells were then treated with vehicle, 15 uM DIM, 10 nM Paclitaxel, and 15 uM 
DIM +10 nM Paclitaxel and incubated for an additional 72 h. Cells were then harvested 
and underwent TUNEL analysis using the ApopTag plus peroxidase in situ apoptosis 
detection kit. 
Western Blot Analysis 
 
435eb1 cells were plated in T-75 flasks and incubated in DMEM/F12 with 10% FBS for 
24 h. Cells were then treated with vehicle, 15 uM DIM, 10 nM Paclitaxel, and 15 uM 
DIM +10 nM Paclitaxel and incubated for an additional 72 h. For determination of 
HER2/neu, phospho-HER2/neu, ERK1/2, and phospho-ERK1/2, cells were incubated in 
serum-free medium overnight and treated with DIM, paclitaxel, and the combination for 
an additional 24 h before stimulation with epidermal growth factor for 15 min. Cells were 
lysed and proteins extracted with cell lysis buffer (Cell Signaling). Proteins were 
separated with SDS-PAGE and transferred to PVDF membrane. The membrane was 
blocked with %0.4 casein (I-Block, Tropix) in PBS-T and then incubated with primary 
antibodies overnight at 4°C. Blots were developed using a horseradish peroxidase-
conjugated secondary antibody and proteins were visualized by enhanced 
chemiluminescence (ECL), scanned with a densitometer (Sharp JX-330), quantitated by 
Image Master 1D, and expressed as arbitrary units relative to the control (β-actin). 
 
 
Statistical Analysis 
 
Cell survival and apoptosis data were analyzed using simple linear regression (equivalent 
to two-way ANOVA) to compare the groups. 
 
 
RESULTS 
 
Effects of DIM on Cell Growth 
 
DIM alone had both a time and concentration dependent  effect on cell growth. After 72 
h; 5 uM DIM decreased cell growth by 23% (SEM ±1.08%), 10 uM DIM decreased cell 
growth by 28% (+/- 1.31%), and 15 uM DIM decreased cell growth by 34% (±2.27%) in 
comparison to control (P < 0.001) (Fig. 1). 
 
 
 
FIG. 1. Increasing concentrations of DIM inhibit cell growth in human breast carcinoma 435 eb1 
cells (Her2/neu positive). Cells were plated in 96-well plates, incubated for 24 h and then treated 
with 0, 5, 10, and 15 uM DIM for 0, 24, 48, and 72 h. The number of viable cells was determined 
with ProCheck cell viability assay. Values represent mean ±SEM. 
 
 
Effects of DIM and Paclitaxel on Cell Growth 
 
DIM and paclitaxel together significantly decreased cell growth when compared to 
control or either treatment alone. After 72 h of incubation, cell growth was inhibited by 
15 uM DIM, 10 nM paclitaxel and the combination of the two treatments by 42% 
(±3.26%), 62%(±1.12%), and 74% (±1.07%), respectively (P < 0.001) (Fig. 2). 
 
 
 
 
FIG. 2. DIM in combination with paclitaxel inhibits cell growth in human breast carcinoma 435 
eb1 cells (Her2/neu positive). Cells were plated in 96-well plates, incubated for 24 h and then 
treated with vehicle, 10 uM DIM, 15 uM DIM, 10 nM paclitaxel, 10 uM DIM +10 nM paclitaxel, 
and 15 uM DIM +10 nM paclitaxel for 0, 24, 48, and 72 h. The number of viable cells was 
determined with ProCheck cell viability assay. Values represent mean ± SEM. 
 
Effects of DIM and Paclitaxel on Cell Cycle 
 
After treatment with 15 uM DIM and 10 nM paclitaxel in a starvation media (5% FBS), a 
small, but not significant increase was seen in the number of cells in the G2M phase of 
the cell cycle (Fig. 3). 
 
 
 
FIG. 3. DIM in combination with paclitaxel induces G2/M cell cycle phase arrest. Cells were 
plated in T-175 flasks, incubated for 24 h and then treated with vehicle, 15 uM DIM, 10 nM 
paclitaxel, and 15 uM DIM _10 nM paclitaxel and incubated for an additional 72 h. Cells were 
then harvested and underwent cell cycle analysis by flow cytometry. 
 
 
Effects of DIM and Paclitaxel on Aapoptosis 
 
The combination of DIM and paclitaxel synergistically increased apoptosis, detected by 
the TUNEL assay, a measure of DNA fragmentation. The combined treatment induced 
apoptosis in 34.8% of treated cells.  The percentage of apoptotic cells was increased in 
435 eb1 cells treated with DIM and paclitaxel compared with vehicle-treated cells 
(control 1.82%, DIM 6.59%, paclitaxel 7.39%) (Fig. 4). 
 
 
 
FIG. 4. DIM in combination with paclitaxel increases apoptosis.  Cells were plated in T-175 
flasks, incubated for 24 h and then treated with vehicle, 15 uM DIM, 10 nM paclitaxel, and 15 uM 
DIM +10 nM paclitaxel and incubated for an additional 72 h. Cells were then harvested and 
underwent TUNEL analysis. 
 
 
Effects of DIM and Paclitaxel on Apoptosis-Related Protein Expression 
 
Protein expression of cleaved poly (ADP-Ribose) polymerase (PARP), an early marker of 
apoptosis, was up regulated in cells treated with DIM and paclitaxel.  Up-regulation was 
synergistically increased by the combination of the two compounds (Fig. 5A).   
 
Expression of the protein, BCL-2, an inhibitor of apoptosis, was significantly reduced in 
samples treated with DIM and paclitaxel. Paclitaxel’s effect on the proapoptotic protein, 
Bax, was not altered by the addition of DIM (Fig. 5B). 
 
Effects of DIM and Paclitaxel on Phosphorylation  
of HER-2/Neu/EGFR and ERK1/2 
 
DIM, paclitaxel, and the combined treatment decreased phosphorylation of the Her2/neu 
receptor (Fig. 6A). We have not measure whether HER3 and HER-4 are present in these 
cells. There does appear to be an additive/synergistic effect when the two agents are 
combined. 
 
However, the protein expression of ERK1/2 and phosph-ERK1/2 decreased in cells 
treated with DIM and paclitaxel and paclitaxel alone. The combination super-additively 
inhibited the activation of ERK1/ERK2. 
 
 
 
 
FIG. 5. DIM in combination with paclitaxel down-regulates BCL-2 expression. However, it 
appears to have little effect on Bax expression.  PARP cleavage and activation is also increased by 
the treatments. Cells were plated in T-75 flasks, incubated for 24 h and then treated with vehicle, 
15 uM DIM, 10 nM paclitaxel, and 15 uM DIM +10 nM paclitaxel and incubated for an additional 
72 h. Cells were then lysed, the proteins were extracted, and Western blot analysis was performed. 
 
 
 
FIG. 6. DIM in combination with paclitaxel down-regulates Her2/neu and ERK1/ERK2 
phosphorylation and activation. Cells were plated in T-75 flasks, incubated for 24 h in 5% 
(starving) media and then treated with vehicle, 15 uM DIM, 10 nM paclitaxel and 15 uM DIM +10 
nM paclitaxel and incubated for an additional 24 h. Cells were then lysed, the proteins were 
extracted, and Western blot analysis was performed. 
 
 
DISCUSSION 
 
DIM and I3C have anticancer effects specifically through cell cycle arrest [7, 12, 14], 
apoptosis [17–19] as well as NF-κB, akt [18, 19], and Bax inhibition [17].  Paclitaxel’s 
effects are mediated by inhibiting microtubule formation [3]. Each of these compounds 
are effective against breast cancer cells with clearly distinct mechanisms of action. 
Compounds similar to DIM, such as resveratrol have been shown to enhance the effects 
of paclitaxel on lung cancer cell lines [6]. In this study we demonstrate for the first time 
that enhances the cytotoxicity of paclitaxel in a breast cancer cell line with 
overexpression of HER2/neu. 
 
The combined treatments induced a greater apoptotic effect than either treatment alone. 
Several pathways leading to apoptosis converge at the mitochrondrial membrane; the 
breakdown of the mitochrondrial membrane is controlled, in part, by the balance of Bcl2 
and Bax in cells. The protein expression of Bcl2 decreased in cells treated with DIM 
alone or the combination of DIM + paclitaxel, whereas there was no change in Bax 
protein expression. Thus, the ratio of Bax to Bcl2 was altered in favor of apoptosis. 
Studies using Her2/neu negative breast cancer cell lines have also shown an effect on the 
Bax/Bcl2 ratio by paclitaxel and DIM [25, 26]. Cleaved PARP, an early marker of 
apoptosis, is formed in significantly greater amounts with the combined treatment than 
with either treatment alone (Fig. 5A) [27]. Interestingly, we found no effect of DIM on 
Bax protein in these cells, an effect previously described in other cell lines [17]. 
However, the concentrations of DIM were as much as ten times higher than those used in 
our study.   
 
Importantly, we observed that DIM decreased the phosphorylation of HER2. Because 
HER2/neu expression confers resistance to the taxanes, DIM may improve the response 
of the 435-eb cells to paclitaxel by down-regulating HER2. Studies have shown that 
combining paclitaxel with Herceptin improved the response of resistant HER2/neu 
overexpressing breast cancer cells to the taxanes [26, 27]. The observation that a nontoxic 
nutrient like DIM that is found in foods may block HER2 signaling may offer clinical 
advantages.  Current therapeutic protocols use the taxanes in combination with Herceptin. 
However, Herceptin is associated with cardiotoxic effects [28] that may be minimized by 
use of DIM. Recent studies have demonstrated that DIM down-regulates the MAPK 
pathway [29]. In this study we demonstrated that ERK1/ERK2 is inhibited more by the 
combination therapy than with either treatment alone. This result suggests that paclitaxel 
may be acting on one of the upstream proteins in the ERK1/ERK2 pathway. In fact, DIM 
has been shown to down-regulate Ras signaling, which is upstream of MAPK [30]. It is 
often the case in cell culture experiments that high concentrations of the agent must be 
used to achieve cytoxic effects. In this study the concentration of DIM (15 _M) found to 
enhance the effectiveness of paclitaxel and alter signaling corresponds to the plasma level 
of humans taking dietary supplements [31]. 
 
In summary, DIM appears to significantly enhance the cytotoxicity of paclitaxel in the 
435eb1 Her2/neu positive, ER/PR negative breast cancer cell line—a cell line known to 
be particularly resistant to taxane treatment both in vitro and in vivo. This effect is 
produced primarily through the up-regulation of apoptosis in the cells treated with a 
combination of DIM and paclitaxel.  Further study into the mechanism of this effect is 
necessary to pinpoint the precise proteins regulated by these compounds and confirm the 
two distinct implicated in this study. In vivo studies will be necessary to confirm not only 
the effectiveness of this combination treatment, but also to evaluate any additional 
cytotoxicity against normal cells. These early studies do suggest that DIM may possibly 
be used clinically as a chemosensitizing agent with taxanes in treatment of traditionally 
taxane-resistant tumors [32,33]. 
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